Preventative treatment plans should consider the individual needs of patients with migraine2
According to the 2019 British Association for the Study of Headache guidelines, patients who experience ≥4 migraine days/month should be offered preventative treatment as an option, as this frequency of migraine is associated with significant disability.2
Prescribing decisions should take into account a patient’s current clinical situation as well as their future plans2
When choosing a preventative treatment, factors to consider include:2
Previous treatment
Personal preferences
Medical and other
comorbidities
Side effect profiles of various treatments
Pregnancy or contraception
AQUIPTA® is not recommended during pregnancy.1
Introducing AQUIPTA®: an oral, once‑daily CGRP receptor antagonist for migraine prevention1,3
AQUIPTA® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days/month. It is a selective CGRP receptor antagonist that blocks the binding of CGRP to the receptor and antagonises CGRP receptor function. By blocking the CGRP‑receptor interaction, AQUIPTA® prevents migraine attacks.1
CGRP levels during a migraine attack
Adapted from Schuster N M et al. 20164
During a migraine attack, levels of the neuropeptide increase.5,6 In the trigeminovascular system, CGRP modulates nociceptive signalling and inflammation, and also functions as a vasodilator,1 inducing pain, inflammation and vasodilation.7
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) GUIDANCE8
AQUIPTA® is recommended by NICE as an option for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventive medicines have failed.8
Stop AQUIPTA® after 12 weeks if the frequency of migraines does not reduce by:8
> At least 50% in episodic migraine (defined as fewer than 15 headache days per month)
> At least 30% in chronic migraine (defined as 15 or more headache days per month, with at least 8 of those having features of migraine)
SCOTTISH MEDICINES CONSORTIUM
(SMC) GUIDANCE9
AQUIPTA® is accepted by SMC for restricted use within NHSScotland for the prophylaxis of migraine in adults who have at least 4 migraine days per month.9
SMC restriction: for patients with chronic and episodic migraine who have had prior failure on three or more migraine preventative treatments.9
AQUIPTA® provides an additional treatment choice in the therapeutic class of CGRP inhibitors.9
WANT TO KNOW MORE ABOUT THE EFFICACY OF AQUIPTA® IN SPECIFIC TYPES OF MIGRAINE?
CGRP: calcitonin gene-related peptide; NICE: National Institute for Health and Care Excellence; SMC: Scottish Medicines Consortium.
Please refer to the AQUIPTA® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The AQUIPTA® Summary of Product Characteristics can be found here.
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.
UK-AQP-250083 | Date of preparation: March 2025.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk
Adverse events should also be reported to AbbVie on GBPV@abbvie.com